Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
10-year-old struck by hit-and-run driver in Rocky Mount
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
4D Molecular Therapeutics Inc
(NQ:
FDMT
)
22.94
+0.33 (+1.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,377,078
Open
22.89
Bid (Size)
21.14 (1)
Ask (Size)
23.30 (1)
Prev. Close
22.61
Today's Range
22.06 - 23.12
52wk Range
9.440 - 36.25
Shares Outstanding
42,052,980
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
June 18, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
June 08, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+7.95%
+7.95%
1 Month
-12.24%
-12.24%
3 Month
-31.73%
-31.73%
6 Month
+10.87%
+10.87%
1 Year
+26.67%
+26.67%
More News
Read More
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Via
Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
June 07, 2024
Via
Benzinga
4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
March 01, 2024
Via
Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 06, 2024
Via
Benzinga
Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released
June 06, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 06, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
February 07, 2024
Via
Benzinga
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
June 06, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
June 04, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
June 03, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
May 30, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conference
May 07, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Announces Presentations at ARVO 2024 Annual Meeting
May 01, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
April 18, 2024
Via
Benzinga
Topics
ETFs
4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease
March 28, 2024
Via
Benzinga
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
March 28, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
March 04, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
February 29, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
February 12, 2024
From
4D Molecular Therapeutics, Inc.
Via
GlobeNewswire
Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?
February 08, 2024
Via
Benzinga
Why 4D Molecular Therapeutics (FDMT) Stock Is Diving
February 07, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.